OB1
0.002
100%
PYC
0.85
-30%
LRD
0.042
82.6%
ORP
0.03
-25%
RCM
0.053
55.9%
VAR
0.006
-25%
JAV
0.003
50%
G88
0.008
-20%
MMR
0.006
50%
NGX
0.16
-20%
CYQ
0.007
40%
WBE
0.004
-20%
CCE
0.105
38.2%
OKJ
0.037
-17.8%
IS3
0.011
37.5%
LML
0.005
-16.7%
SFM
0.295
37.2%
CXU
0.011
-15.4%
AA2
0.39
34.5%
KTA
0.011
-15.4%
AQC
0.008
33.3%
M4M
0.006
-14.3%
COY
0.016
33.3%
NWM
0.012
-14.3%
CZN
0.004
33.3%
ICR
0.025
-13.8%
MOH
0.008
33.3%
KLR
0.29
-13.4%
CNQ
0.34
30.8%
BMN
3.27
-12.8%
AQX
0.005
25%
ANX
0.007
-12.5%
CNJ
0.005
25%
SW1
0.007
-12.5%
RLG
0.005
25%
VKA
0.007
-12.5%
DBO
0.036
24.1%
TMB
0.043
-12.2%
RIM
0.016
23.1%
EMV
2.05
-11.6%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Nyrada Inc. (ASX:NYR): Developing NYR-BI03

Nyrada Inc. (ASX:NYR) has made progress on developing NYR-BI03, a first in class neuroprotection treatment for both traumatic brain injury (TBI) and stroke.

– Additional study provided further data to support safety and tolerability of Nyrada’s lead Brain Injury drug candidate.

– Rat CNS testing satisfactorily completed under Good Laboratory Practice (GLP) conditions for NYR-BI03.

– Nyrada will continue to report on remaining GLP study results and remains on track to commence first in-human Phase I clinical trial for NYR-BI03 in late CY2024

ASX announcement: https://announcements.asx.com.au/asxpdf/20240806/pdf/066by3mf9gs2jy.pdf